Pharma Pulse: Cholesterol Imbalance Tied to Depression Risk, Lilly Acquires Aderum Biotechnologies, and Cambrex Expands API Manufacturing

This episode of Pharma Pulse discusses new research linking cholesterol imbalance in obesity to higher depression risk, Eli Lilly’s acquisition of Aderum Biotechnologies to strengthen its neuroscience pipeline, and Cambrex’s $120 million investment to boost US API manufacturing capacity.